RE:RE:RE:April 22, 2015digitel wrote: "cost of plant and how that would get paid"
They were suppose to have their new plant operational last year. They didn't deliver and the volitility in earnings and the failure to deliver left questions about financing and execution. They have also renewed their agreement with Symrise this year.
COV.v is another interesting medical company with revenues and emerging profitability. It looks like a multi-bagger and not much has to happen to get there. They have an increasingly diversified revenue base by product and geography and are very undervalued, it appears.
Been buying a few COV.V here myself too.... great minds think alike ;)